Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that.
NRx Pharmaceuticals, Inc. , ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per.
NRx Pharmaceuticals (NRXP) Reports Q4, Provides Business Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend
RADNOR, Pa., March 28, 2024 /PRNewswire/ NRx Pharmaceuticals, Inc. , a.
NRx Pharmaceuticals (NRXP) Reports Prelim FY23 Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.